Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy
Retrospective analysis shows promise of daratumumab with dexamethasone in multiple myeloma after bortezomib failure, highlighting transplant outcomes.
Key Points
Overall, 50% of patients showed measurable residual disease negativity after daratumumab treatment, which is promising for myeloma management.
In a small salvage group, 75% achieved a very good partial response after daratumumab treatment, demonstrating its potential efficacy.
Patients receiving dexamethasone-based therapy had a 2-year treatment-free survival of 88%, compared to 49% in controls, offering a potential advantage after ASCT.
However, hypogammaglobulinemia occurred in 75% of the salvage patients, indicating a risk with this therapeutic approach.